374 related articles for article (PubMed ID: 27477692)
1. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
2. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
3. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance.
Hu J; Xia X; Zhao Q; Li S
Cancer Lett; 2021 Apr; 502():143-153. PubMed ID: 33279621
[TBL] [Abstract][Full Text] [Related]
4. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
[TBL] [Abstract][Full Text] [Related]
5. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
6. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.
Lam AR; Bert NL; Ho SS; Shen YJ; Tang LF; Xiong GM; Croxford JL; Koo CX; Ishii KJ; Akira S; Raulet DH; Gasser S
Cancer Res; 2014 Apr; 74(8):2193-2203. PubMed ID: 24590060
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity.
Xu X; Rao G; Li Y
Oncotarget; 2016 Sep; 7(37):59220-59235. PubMed ID: 27494876
[TBL] [Abstract][Full Text] [Related]
8. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
10. A conserved WW domain-like motif regulates invariant chain-dependent cell-surface transport of the NKG2D ligand ULBP2.
Uhlenbrock F; van Andel E; Andresen L; Skov S
Mol Immunol; 2015 Aug; 66(2):418-27. PubMed ID: 25983110
[TBL] [Abstract][Full Text] [Related]
11. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
12. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8
Hu J; Bernatchez C; Zhang L; Xia X; Kleinerman ES; Hung MC; Hwu P; Li S
Cancer Immunol Res; 2017 Apr; 5(4):300-311. PubMed ID: 28223282
[TBL] [Abstract][Full Text] [Related]
13. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
14. A dual function of NKG2D ligands in NK-cell activation.
Cheney EE; Wise EL; Bui JD; Schreiber RD; Carayannopoulos LN; Spitzer D; Zafirova B; Polic B; Shaw AS; Markiewicz MA
Eur J Immunol; 2012 Sep; 42(9):2452-8. PubMed ID: 22740149
[TBL] [Abstract][Full Text] [Related]
15. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
17. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
18. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
[TBL] [Abstract][Full Text] [Related]
20. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
